▲ +205.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Eiger BioPharmaceuticals in the last 3 months. The average price target is $25.00, with a high forecast of $28.00 and a low forecast of $22.00. The average price target represents a 205.62% upside from the last price of $8.18.
The current consensus among 2 investment analysts is to buy stock in Eiger BioPharmaceuticals. This Buy consensus rating has held steady for over two years.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.